↓ Skip to main content

Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Relapsed Ewing Sarcoma: Results of a Basket Phase II StudyAntitumor activity of lurbinectedin in relapsed ES

Overview of attention for article published in Clinical Cancer Research, April 2022
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
8 news outlets
twitter
143 X users
facebook
1 Facebook page

Citations

dimensions_citation
13 Dimensions

Readers on

mendeley
16 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Relapsed Ewing Sarcoma: Results of a Basket Phase II StudyAntitumor activity of lurbinectedin in relapsed ES
Published in
Clinical Cancer Research, April 2022
DOI 10.1158/1078-0432.ccr-22-0696
Pubmed ID
Authors

Vivek Subbiah, Irene Brana, Alessandra Longhi, Valentina Boni, Jean-Pierre Delord, Ahmad Awada, Pascaline Boudou-Rouquette, John Sarantopoulos, Geoffrey I. Shapiro, Anthony Elias, Ravin Ratan, Cristian Fernandez, Carmen Kahatt, Martin Cullell-Young, Mariano Siguero, Ali Zeaiter, Sant P. Chawla

X Demographics

X Demographics

The data shown below were collected from the profiles of 143 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 16 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 2 13%
Researcher 1 6%
Other 1 6%
Student > Master 1 6%
Unknown 11 69%
Readers by discipline Count As %
Medicine and Dentistry 3 19%
Agricultural and Biological Sciences 1 6%
Biochemistry, Genetics and Molecular Biology 1 6%
Unknown 11 69%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 140. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 July 2023.
All research outputs
#295,168
of 25,364,936 outputs
Outputs from Clinical Cancer Research
#124
of 13,211 outputs
Outputs of similar age
#8,328
of 445,864 outputs
Outputs of similar age from Clinical Cancer Research
#2
of 127 outputs
Altmetric has tracked 25,364,936 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,211 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.7. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 445,864 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 127 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.